Oral minoxidil in the UK: licensed for something else

What the UK licences actually say

Search the UK's electronic medicines compendium for minoxidil tablets and you find products licensed for one thing. Minoxidil 5 mg Tablets — the record read for this page is PL 49578/0016, held by Roma Pharmaceuticals Ltd, revised 23 June 2026 — are Prescription only medicine, and are "indicated for the treatment of severe hypertension".

The branded record says the same and adds a clause. Loniten 5 mg Tablets, prescription only, revised February 2026: "Minoxidil is indicated for the treatment of severe hypertension. It should not be used as the sole agent to initiate therapy."

Not one of them names hair loss. That is the fact this whole page rests on: in the UK, an oral minoxidil tablet is a blood-pressure medicine, and any use of it for hair is use outside the terms of the licence.

What "off-label" means, and who it belongs to

Prescribing a licensed medicine for something its licence does not cover is lawful in the UK, and it is a decision that belongs entirely to a prescriber. It shifts a set of responsibilities onto that prescriber: the judgement that it is appropriate for this patient, the monitoring, and the explanation of why a medicine licensed for one purpose is being used for another.

None of those responsibilities can be taken on by a reader, a website or a forum, which is why this page carries no dose, no schedule, no comparison of strengths and no view about whether anybody should be taking it. The one useful thing a reference page can do here is show you what the prescriber is holding.

What the tablet's own label warns about

The Loniten record is unusually direct, and its warnings are about the cardiovascular system rather than about hair.

It is not meant to be used alone. "Minoxidil must be given in conjunction with a diuretic in sufficient dosage to maintain salt and water balance." And: "Patients will require a sympathetic nervous system suppressant to limit a minoxidil-induced rise in heart rate. The preferred agent is a beta-blocker."

Used alone, it retains fluid. "If used alone, minoxidil can cause a significant retention of salt and water leading to physical signs such as oedema."

There is a specific cardiac complication with a published frequency. "Pericardial effusion and occasionally tamponade, has been observed in about 3% - 5% of treated patients."

And a rate effect. "Reflex tachycardia may occur and possibly angina pectoris may occur in patients at risk."

Those figures and phrases come from a label written for the treatment of severe hypertension, where the medicine is given with two other drugs and under supervision. They are not a prediction about anybody using it for another purpose, and this page will not translate them into one. They are here because they explain, better than any argument, why the UK system puts this tablet behind a prescription and why a prescriber considering it off-label is doing something that requires monitoring rather than a delivery.

The topical is a different legal object entirely

It is easy to lose sight of how far apart these two things sit in UK law. The topical is general sale: Regaine for Men Extra Strength Scalp Solution 5% holds marketing authorisation PL 15513/0365 with the legal category General Sales List, and is indicated for the treatment of alopecia androgenetica in men. A shop may sell it.

The tablet is prescription only and licensed for severe hypertension. Same molecule; completely different products, licences and routes into the body. The comparison people want — whether one works better than the other — is not a UK regulatory question and is not answered here. The distance between them in law is drawn out in what is licensed for hair loss in the UK.

Why you will not see it advertised

You will not, and that is also the rule rather than an accident. The Advertising Standards Authority's guidance is that prescription-only medicines must not be advertised to the public, under CAP Code rule 12.12, and it names prescription-strength minoxidil among the things that cannot be promoted to a public audience. A clinic may advertise a consultation; the treatment itself is out of bounds.

So when a UK service refers vaguely to "oral options" or "tablet treatments" without naming anything, that is compliance, not mystery. How much else in a UK advert is shaped by the same rules is worked through in reading a UK hair clinic advert.

If a prescriber has raised it with you

Then the conversation is already in the right place, and the questions worth asking are about monitoring rather than about the molecule. What will be checked, how often, and what would cause the prescriber to stop. What symptoms should prompt a call rather than a wait. Whether anything else you take interacts with it. And what the plan is if it is working — because a medicine used off-label for a chronic condition has no natural end point and that ought to be discussed at the start rather than discovered later.

If you found it online instead, the useful comparison is not between the tablet and the bottle. It is between a medicine supervised by somebody who knows your blood pressure and a medicine that is not.

Where to start instead

If the question underneath all this is "what can I do about my hair in the UK", the ordered version is: find out what kind of hair loss it is, which the NHS will do for nothing — what the NHS funds and does not fund explains why that step comes first. Then look at what is licensed here and at what legal distance, which is hair loss treatment in the UK. And if surgery is in the frame, the registers come before the quotes: hair transplants in the UK.